Published in Proc Natl Acad Sci U S A on January 02, 2001
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol (2002) 0.97
Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J Virol (2010) 0.96
Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy. BMC Infect Dis (2009) 0.93
Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol (2004) 0.86
Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol (2014) 0.84
Genetic modification of hematopoietic stem cells as a therapy for HIV/AIDS. Viruses (2013) 0.80
CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol (2009) 0.79
Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr (2013) 0.75
HIV infection: what should be considered in approaches for a cure? AIDS (2012) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis (1985) 3.31
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology (1992) 2.71
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med (1998) 2.50
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol (1999) 2.30
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol (1988) 1.78
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology (1988) 1.64
Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet (1994) 1.40
HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA (1994) 1.36
Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A (1999) 1.27
Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis (1993) 1.17
Role of beta-chemokines in suppressing HIV replication. Science (1996) 1.13
Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr (1994) 1.10
Inhibition of immune functions by antiviral drugs. J Clin Invest (1991) 1.04
Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis (1999) 1.03
Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol (2000) 0.98
CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. J Infect Dis (1999) 0.92
Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS (2000) 0.83
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA (1987) 7.24
Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains. Science (1973) 7.12
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health (1987) 5.78
Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc Natl Acad Sci U S A (1987) 5.65
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med (1996) 5.56
Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature (1982) 4.93
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 4.51
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Human immunodeficiency viruses. Science (1986) 4.34
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet (1997) 3.93
Condoms prevent transmission of AIDS-associated retrovirus. JAMA (1986) 3.78
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet (1996) 3.54
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
Brucella abortus 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class Proteobacteria. J Bacteriol (1990) 3.36
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis (1985) 3.31
Consensus statement on the live organ donor. JAMA (2000) 3.29
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23
Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet (1988) 3.21
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Molecular cloning of AIDS-associated retrovirus. Nature (1985) 3.16
Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A (1987) 3.14
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 3.00
Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet (1985) 2.88
Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol (1991) 2.87
Human lymphoblastoid lines from lymph node and spleen. Cancer (1968) 2.85
Demonstration of biological activity of a murine leukemia virus of New Zealand black mice. Science (1970) 2.79
Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells. J Bacteriol (1966) 2.79
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis (1997) 2.75
Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol (1990) 2.72
The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health (1988) 2.69
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med (1995) 2.63
Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus. Science (1985) 2.58
Protease inhibitors in the homeless. JAMA (1997) 2.57
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A (1994) 2.48
Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant (2006) 2.47
Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet (1986) 2.43
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
Studies with hydroxyurea. I. The reversible inhibition of bacterial DNA synthesis and the effect of hydroxyurea on the bactericidal action of streptomycin. Biochim Biophys Acta (1966) 2.42
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A (1988) 2.37
Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA (1998) 2.36
Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.35
AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science (1986) 2.34
A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology (1989) 2.33
Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis (1987) 2.32
Preventive health care for adults with HIV infection. JAMA (1993) 2.29
CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A (1995) 2.27
Differential effects of nef on HIV replication: implications for viral pathogenesis in the host. Science (1989) 2.25
Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion. Am J Epidemiol (2001) 2.22
Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. Ann Intern Med (1985) 2.15
Autoimmunity and neoplasia. The possible role of C-type viruses. Am J Clin Pathol (1974) 2.09
Improving on a coin toss to predict patient adherence to medications. Ann Intern Med (2001) 2.06
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Murine xenotropic type C viruses I. Distribution and further characterization of the virus in NZB mice. J Virol (1975) 2.02
Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc Natl Acad Sci U S A (1975) 2.01
Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol (1990) 2.00
Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A (1984) 1.99
Prevalence of antibodies to AIDS-associated retrovirus in single men in San Francisco. Lancet (1985) 1.98
Alzheimer's disease: immunoreactivity of neurofibrillary tangles with anti-neurofilament and anti-paired helical filament antibodies. Brain Res (1984) 1.98
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science (1993) 1.97
Antigen conformation determines processing requirements for T-cell activation. Proc Natl Acad Sci U S A (1984) 1.94
Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group. Ann Intern Med (1999) 1.94
Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet (1991) 1.92
Adherence: a necessity for successful HIV combination therapy. AIDS (1999) 1.91
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol (1990) 1.90
Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature (1996) 1.90
An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol (1993) 1.89
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis (1987) 1.86
Alzheimer's paired helical filaments share epitopes with neurofilament side arms. EMBO J (1986) 1.81
Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology (1986) 1.81
Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol (1988) 1.79
Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol (1988) 1.78
Xenotropic type C viruses. Curr Top Microbiol Immunol (1978) 1.78
CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses (1992) 1.75
Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression. Science (1988) 1.72
Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol (1991) 1.72
Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis (1994) 1.71
Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol (1994) 1.70
Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS (1994) 1.68
Long-term cultivation of T-cell subsets from patients with acquired immune deficiency syndrome. Clin Immunol Immunopathol (1985) 1.65